Skip to main
ALEC

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 0%
Sell 25%
Strong Sell 0%

Bulls say

Alector Inc. is positioned favorably in the biopharmaceutical market due to its innovative approach in developing therapies aimed at treating neurodegeneration by restoring healthy immune function in the brain. The company's dynamic approach, targeting the transferrin receptor (TfR), indicates potential improvements in both central nervous system (CNS) delivery and systemic effectiveness, as demonstrated by significant increases in brain uptake and favorable safety signals from their ABC platform. Furthermore, with promising lead programs addressing larger indications and more standardized AD biomarkers, early clinical proof-of-concept data could result in substantial upside potential for the company's stock.

Bears say

Alector's stock outlook has been negatively impacted by the failure of the INFRONT-3 trial for latozinemab, which did not meet its primary endpoint, thereby introducing significant translational biology risks and suggesting inefficiencies in PGRN transport mechanisms. The company's pipeline products, including AL001, AL002, and AL101, are also subject to substantial risks associated with their clinical trials, which may not secure regulatory approval or meet projected revenue expectations. Concerns regarding potential negative outcomes in ongoing trials, along with risks of off-target toxicity, further undermine investor confidence.

Alector Inc (ALEC) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 4 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.